Pharmicell (005690.KS) Earnings Analysis

Pharmicell (005690.KS) next reports earnings on 2026-08-19, consensus EPS 213 KRW. Last quarter (2026-02-09) it beat with EPS 262 KRW vs 262 KRW est (0%). It has beaten estimates in 1/1 recent quarters (100%). Trailing P/E 15.40.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 005690.KS next report earnings?

Next earnings date2026-08-19
Consensus EPS estimate213 KRW
Revenue estimate42.10B

005690.KS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-02-09262 KRW262 KRW0%Beat
2025-08-11123 KRWn/an/an/a
2025-02-1069.23 KRWn/an/an/a

Beat rate: 1/1 (100%) over reported quarters with consensus data.

005690.KS valuation and analyst view

Trailing P/E15.40
Trailing EPS726.29 KRW
Price / book5.05
Dividend yield0.45%
Market cap643.24B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Pharmicell (005690.KS)'s next earnings date?

Pharmicell is next scheduled to report on 2026-08-19, with a consensus EPS estimate of 213 KRW and revenue estimate of 42.10B.

Did 005690.KS beat earnings last quarter?

In its 2026-02-09 report, 005690.KS posted EPS of 262 KRW versus a 262 KRW estimate — a beat of 0%.

What is 005690.KS's earnings track record?

Over the last 1 reported quarters with consensus data, 005690.KS beat estimates 1 times (100%).

What is 005690.KS's current P/E ratio and EPS?

005690.KS trades at a trailing P/E of 15.40 on trailing EPS of 726.285420305313 KRW.

What do analysts rate 005690.KS?

005690.KS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.